IRIS
SIMONELLI, Matteo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.013
AS - Asia 3.152
EU - Europa 1.153
SA - Sud America 753
AF - Africa 176
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 3
Totale 10.256
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.914
SG - Singapore 1.964
BR - Brasile 606
CN - Cina 450
VN - Vietnam 305
FI - Finlandia 228
IT - Italia 204
IE - Irlanda 163
DE - Germania 128
NG - Nigeria 117
FR - Francia 93
HK - Hong Kong 91
SE - Svezia 75
GB - Regno Unito 72
CA - Canada 65
IN - India 60
AR - Argentina 54
NL - Olanda 52
TR - Turchia 45
BD - Bangladesh 37
ID - Indonesia 31
IQ - Iraq 28
EC - Ecuador 26
IL - Israele 25
PL - Polonia 25
RU - Federazione Russa 18
JP - Giappone 17
MX - Messico 17
BE - Belgio 16
ZA - Sudafrica 16
CL - Cile 15
CO - Colombia 15
VE - Venezuela 14
PK - Pakistan 13
UA - Ucraina 13
SA - Arabia Saudita 12
ES - Italia 11
PY - Paraguay 10
MA - Marocco 9
AT - Austria 8
DZ - Algeria 7
EG - Egitto 7
PH - Filippine 7
TN - Tunisia 7
UY - Uruguay 7
UZ - Uzbekistan 7
LT - Lituania 6
AE - Emirati Arabi Uniti 5
BG - Bulgaria 5
KZ - Kazakistan 5
MY - Malesia 5
CZ - Repubblica Ceca 4
EU - Europa 4
GE - Georgia 4
IR - Iran 4
JM - Giamaica 4
KE - Kenya 4
LB - Libano 4
PE - Perù 4
TW - Taiwan 4
AU - Australia 3
AZ - Azerbaigian 3
CH - Svizzera 3
DO - Repubblica Dominicana 3
HU - Ungheria 3
LV - Lettonia 3
PS - Palestinian Territory 3
PT - Portogallo 3
RO - Romania 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AL - Albania 2
AM - Armenia 2
BA - Bosnia-Erzegovina 2
BO - Bolivia 2
BY - Bielorussia 2
CG - Congo 2
CR - Costa Rica 2
ET - Etiopia 2
GA - Gabon 2
GR - Grecia 2
HN - Honduras 2
HR - Croazia 2
JO - Giordania 2
KG - Kirghizistan 2
KR - Corea 2
KW - Kuwait 2
LK - Sri Lanka 2
MD - Moldavia 2
MK - Macedonia 2
NP - Nepal 2
OM - Oman 2
PA - Panama 2
AF - Afghanistan, Repubblica islamica di 1
BB - Barbados 1
BH - Bahrain 1
BN - Brunei Darussalam 1
CI - Costa d'Avorio 1
DK - Danimarca 1
DM - Dominica 1
KH - Cambogia 1
Totale 10.247
Salva come PNG Salva come JPEG
Città #
Singapore 888
Wilmington 706
Chandler 508
Ashburn 404
Dallas 354
The Dalles 315
San Mateo 299
Helsinki 227
Shanghai 216
San Jose 192
Ann Arbor 189
New York 187
Dublin 163
Lawrence 127
Princeton 127
Leawood 119
Benin City 117
Ho Chi Minh City 104
Beijing 100
Hong Kong 88
Milan 88
Woodbridge 81
Boardman 80
Paris 71
Phoenix 63
Hanoi 62
São Paulo 62
Fairfield 60
Los Angeles 47
Amsterdam 43
Toronto 41
London 38
Santa Clara 32
Seattle 30
Kocaeli 29
Orem 22
Warsaw 22
San Diego 21
Naples 19
Rio de Janeiro 18
Da Nang 16
Belo Horizonte 15
Brussels 15
Pune 15
Chennai 13
Council Bluffs 13
Norwalk 12
Baghdad 11
Boston 11
Guayaquil 11
Haiphong 11
Porto Alegre 11
Tokyo 11
Hillsboro 10
Curitiba 9
Manchester 9
Montreal 9
Stockholm 9
Abbiategrasso 8
Brasília 8
Buffalo 8
Columbus 8
Denver 8
Erbil 8
Monmouth Junction 8
Munich 8
Santiago 8
Brooklyn 7
Chicago 7
Dhaka 7
Falkenstein 7
Fortaleza 7
Johannesburg 7
Mexico City 7
Reston 7
San Francisco 7
Tashkent 7
Thái Nguyên 7
Atlanta 6
Biên Hòa 6
Buenos Aires 6
Genoa 6
Goiânia 6
Guarulhos 6
Montevideo 6
Moscow 6
New Delhi 6
Quito 6
Charlotte 5
Des Moines 5
Karachi 5
Manaus 5
Nanjing 5
Pretoria 5
Redmond 5
Riyadh 5
Uberlândia 5
Ankara 4
Aracaju 4
Assago 4
Totale 6.836
Salva come PNG Salva come JPEG
Nome #
Carbon-11-methionine PET-CT as an imaging biomarker in brain gliomas eligible for surgery 124
Cerebrospinal fluid tumor DNA for liquid biopsy in glioma patients’ management: close to clinic 121
Association of Supratotal Resection with Progression-Free Survival, Malignant Transformation, and Overall Survival in Lower-Grade Gliomas 120
Administration of temozolomide during and after radiotherapy for newly diagnosed high-grade gliomas excluding glioblastoma multiforme 119
Are three weeks hypofractionated radiation therapy (HFRT) comparable to six weeks for newly diagnosed glioblastoma patients? Results of a phase II study 118
VINORELBINE (V) IN PEMETREXED-PRETREATED PATIENTS (PTS) WITH MALIGNANT PLEURAL MESOTHELIOMA (MPM) 116
COVID-19 and liver cancer clinical trials: not everything is lost 107
A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis 105
Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with solid tumors 105
Treatment of malignant pleural mesothelioma: current status and future directions 103
NaCl enhances CD8+ T cell effector functions in cancer immunotherapy 101
Addition of temozolomide to radiotherapy for treatment of newly diagnosed anaplastic gliomas 101
Correlation of microvascular fractal dimension with positron emission tomography [C-11]-methionine uptake in glioblastoma multiforme: Preliminary findings 100
Checkpoint inhibitors as treatment for malignant gliomas: "A long way to the top" 100
Advances in the biology of malignant pleural mesothelioma 100
Role of Myeloid Cells in the Immunosuppressive Microenvironment in Gliomas 100
Hypofractionated radiation therapy (HFRT) versus conventional fractionated radiation therapy (CRT) for newly diagnosed glioblastoma patients. A propensity score matched analysis. 99
Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma 98
PHASE II STUDY OF THE COMBINATION OF BEVACIZUMAB PLUS PEMETREXED AND CARBOPLATIN AS FIRST-LINE THERAPY IN PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA (MPM) 94
Checkpoint Inhibitors as High-Grade Gliomas Treatment: State of the Art and Future Perspectives 91
Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors 87
Multimodal Characterization of Supratentorial Gliomas: Relationship Among Morphological, Metabolic and Molecular features 86
Thymoma associated with myasthenia and autonomic anti-Hu paraneoplastic neuropathy 85
Multimodality therapy approaches, local and systemic treatment, compared with chemotherapy alone in recurrent glioblastoma 85
Reproducibility of the WHO classification of thymomas: practical implications 85
Insulin-Like Growth Factor-1 Receptor and Phosphorylated AKT-Serine 473 Expression in 132 Resected Thymomas and Thymic Carcinomas 85
COVID-19 lung injury as a primer for immune checkpoint inhibitors (ICIs)-related pneumonia in a patient affected by squamous head and neck carcinoma treated with PD-L1 blockade: a case report 85
FDG-PET as a tool to optimize residual surgery in patients with primary extragonadal germ cell tumors: preliminary results 84
Changes in shedding of soluble tumor necrosis factor receptors (sR1/R2) and in dynamic MRI as early predictors of outcome with NGR-hTNF 84
Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors 84
Targeted therapy for thymic epithelial tumors: a new horizon ? Review of the literature and two cases reports 83
Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1 in patients with hepatocellular carcinoma 83
Prognostic and predictive role of [F-18]fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy 82
Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy 82
Conducting Phase I Trials During the SARS-Coronavirus-2 Outbreak: About Science and Care 82
Infertility risk and teratogenicity of molecular targeted anticancer therapy: a challenging issue 81
Investigation on the role of integrated PET/MRI for target volume definition and radiotherapy planning in patients with high grade glioma 81
Herpes infections in breast cancer patients treated with adjuvant chemotherapy 81
Response to Sunitinib in an Adult Patient With Rhabdoid Renal Cell Carcinoma 80
Role of surgical resection in recurrent glioblastoma: prognostic factors and outcome evaluation in an observational study. 80
Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study 80
Second-line chemotherapy in malignant pleural mesothelioma: Results of a retrospective multicenter survey 79
Neutrophils in Gliomas 79
Phase II Study of Asparagine-Glycine-Arginine-Human Tumor Necrosis Factor alpha, a Selective Vascular Targeting Agent, in Previously Treated Patients With Malignant Pleural Mesothelioma 79
The 70-year-old newly diagnosed glioblastoma patients are older than the 65-year-old? Outcome evaluation of the two categories in a matched case control study with propensity score balancing 79
High-grade gliomas (HGGs) and immunotherapeutic early-phase clinical trials (ieCTs): A single-center experience 78
HIGH-GRADE GLIOMAS AND IMMUNOTHERAPEUTIC EARLY PHASE CLINICAL TRIALS: A SINGLE-CENTER EXPERIENCE 78
Maximize surgical resection beyond contrast-enhancing boundaries in newly diagnosed glioblastoma multiforme: is it useful and safe? A single institution retrospective experience 77
Value of Surgical Resection in Patients with Newly Diagnosed Grade III Glioma Treated in a Multimodal Approach: Surgery, Chemotherapy and Radiotherapy 76
Temozolomide combined with radiotherapy in the treatment of recurrent cranial meningioma previously treated with multiple surgical resections and two sessions of radiosurgery: a case report and literature review. 76
Pathological characterization of nivolumab –related liver injury in a patient with glioblastoma 75
Phase II study of hypofractionated radiation therapy in elderly patients with newly diagnosed glioblastoma with poor prognosis 75
Thymidylate Synthase and Excision Repair Cross-Complementing Group-1 as Predictors of Responsiveness in Mesothelioma Patients Treated with Pemetrexed/Carboplatin 74
Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma 74
Is IDH status the only factor predicting prognosis in newly diagnosed anaplastic glioma patients? Outcome evaluation and prognostic factor analysis in a single-institution large series 73
The Role of Pemetrexed in the Pharmacotherapy of Malignant Pleural Mesothelioma 73
Precision Oncology in Lower-Grade Gliomas: Promises and Pitfalls of Therapeutic Strategies Targeting IDH-Mutations 72
THE ROLE OF THYMIDTYLATE SYNTHASE (TS) AND EXCISION REPAIR CROSS-COMPLEMENTING GROUP 1 (ERCC1) IMMUNOHISTOCHEMICAL EXPRESSION IN MALIGNANT PLEURAL MESOTHELIOMA (MPM) PATIENTS TREATED WITH PEMETREXED AND CARBOPLATIN 72
Outcome evaluation of patients with newly diagnosed anaplastic gliomas treated in a single institution 71
Is surgical resection useful in elderly newly diagnosed glioblastoma patients? Outcome evaluation and prognostic factors assessment 71
Tivantinib: a new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma 71
Role of surgical resection in recurrent glioblastoma: prognostic factors and outcome evaluation in a observational study 70
HYPOFRACTIONATED RADIATION THERAPY (OVER 3 WEEKS) CAN REPLACE CONVENTIONAL RADIATION THERAPY SCHEDULE (OVER 6 WEEKS) IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS? THE TIMES ARE RIPE 70
Is supratotal resection achievable in low-grade gliomas? Feasibility, putative factors, safety, and functional outcome 69
Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma 69
Imaging biomarkers in primary brain tumours 69
Expression of the transcription factor HEY1 in glioblastoma: a preliminary clinical study 68
Phase I, pharmacokinetics, pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors 68
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal 68
Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors 67
IMPACT OF SOLUBLE TUMOR NECROSIS FACTOR-RECEPTORS (STNF-RS) SHEDDING ON OUTCOME IN PATIENTS TREATED WITH NGR-HTNF 67
Editorial for "Noninvasive Assessment of MGMT Promoter Methylation Status in World Health Organization Grade II-IV Glioma Using Histogram Analysis of Inflow-Based Vascular-Space Occupancy Combined with Structural MR Imaging" 67
Depatuxizumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO) 66
Lower Grade Gliomas: Relationships Between Metabolic and Structural Imaging with Grading and Molecular Factors 65
Cardiac MRI study of adverse events in patients treated with immune checkpoint inhibitors: a prospective cohort study of cardiac adverse events 64
Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study 64
PHASE I AND PHARMACODYNAMIC STUDY OF NGR-HTNF ADMINISTERED AT HIGH DOSES IN REFRACTORY PATIENTS WITH SOLID TUMORS 64
High-dose chemotherapy followed by autologous hematopoietic stem-cell transplantation for the treatment of solid tumors in adults: a critical review 63
Role of 11C Methionine Positron Emission Tomography (11CMETPET) for Surgery and Radiation Therapy Planning in Newly Diagnosed Glioblastoma Patients Enrolled into a Phase II Clinical Study 63
Immunotherapeutic early-phase clinical trials and malignant gliomas: A single-center experience and comprehensive immunophenotyping of circulating leukocytes 63
Clinicopathological and molecular landscape of 5-year IDH-wild-type glioblastoma survivors: A multicentric retrospective study 62
Phase I study of NGR-hTNF administered at high doses in refractory patients with solid tumors 62
Reliability of the HER2 status assessment by immunohistochemistry for breast cancer patients after preoperative chemotherapy 62
Vinorelbine as second or third-line therapy in pemetrexed-pretreated malignant pleural mesothelioma (MPM) patients 62
Electrolyte abnormalities and side effects of zoledronate in patients with bone metastases 61
Future developments in the management of malignant pleural mesothelioma 61
Optimizing residual surgery for patients with primary extragonadal germ cell tumors 60
Phase II study of hypofractionated radiation therapy with concomitant and adjuvant Temozolomide following surgical resection for patients with newly diagnosed glioblastoma:preliminary evaluation 60
Three-day low-dose Cisplatin administration in advanced non-small cell lung cancer (NSCLC): Efficacy and reduced toxicity 60
Mismatch-Repair Protein Expression in High-Grade Gliomas: A Large Retrospective Multicenter Study 60
Risks of molecular targeted therapies to fertility and safety during pregnancy: a review of current knowledge and future needs 60
Supratotal resection in newly diagnosed GBMs: role of this surgical strategy beyond enhancing boundaries 59
Phase Lib trial of tivantinib in combination with carboplatin and pernetrexed as first-line treatment in patients (pts) with advanced nonsquamous NSCLC or malignant pleural mesotheliorna (MPM) 59
Pembrolizumab (MK-3475) for PD-L1-positive squamous cell carcinoma (SCC) of the anal canal: Preliminary safety and efficacy results from KEYNOTE-028 59
High incidence of hypocalcemia in patients with bone metastases from different kinds of neoplasms, treated with zoledronate 59
Prognostic relevance of temporal muscle thickness as a marker of sarcopenia in patients with glioblastoma at diagnosis 59
Outcome evaluation of patients with diagnosed WHO grade III glioma treated according to the molecular profile, the hystology, and the extent of resection (EOR) 58
Intensified chemotherapy with stem-cell rescue in germ-cell tumors 58
Phase I, pharmacokinetic (PK), pharmacodynamic (PD) study of lapatinib (L) in combination with sorafenib (S) in patients with advanced refractory solid tumors 58
First-In-Human Phase I Study of a Next-Generation, Oral, Transforming Growth Factor-Beta Receptor 1 Inhibitor, LY3200882 in Patients with Advanced Cancer 58
Totale 7.830
Salva come PNG Salva come JPEG
Categoria #
all - tutte 69.610
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 69.610
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021372 0 0 0 0 0 0 0 0 0 185 17 170
2021/2022689 32 5 13 139 4 6 28 102 55 71 199 35
2022/20231.536 285 66 162 148 120 99 3 119 261 153 107 13
2023/20241.113 58 108 171 39 45 251 88 47 11 32 109 154
2024/20251.553 33 17 10 27 33 162 64 166 270 359 197 215
2025/20264.061 609 416 370 484 134 264 1.095 241 236 212 0 0
Totale 10.422